---
title: "Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287276376.md"
description: "Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News"
datetime: "2026-05-21T13:40:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287276376.md)
  - [en](https://longbridge.com/en/news/287276376.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287276376.md)
generator: "portal-rs"
---

# Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

### Related Stocks

- [ZNTL.US](https://longbridge.com/en/quote/ZNTL.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Walters Group reports purchase of 4,335,000 Zentalis shares for $15.17 million](https://longbridge.com/en/news/296406214.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [BUZZ-Zentalis Pharma falls on $81 mln stock sale](https://longbridge.com/en/news/295923711.md)
- [Zentalis closes 26,450,000-share public offering at $3.5 per share, raises $92.6 million gross](https://longbridge.com/en/news/296140535.md)
- [Zentalis says DENALI Phase 2 topline data for azenosertib expected in 1H 2027](https://longbridge.com/en/news/295143671.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**